The SEWER Act (H.R. 766) amends the Public Health Service Act to expand and coordinate the National Wastewater Surveillance System. It directs the Secretary of HHS, through the CDC Director, to intensify detection and monitoring of pathogens in wastewater and to award grants, contracts, or cooperative agreements to eligible entities to establish, maintain, or improve wastewater-based infectious disease surveillance.
The bill names specific pathogens for monitoring (for example SARS–CoV–2, influenza, mpox, dengue, West Nile virus, and RSV), authorizes $150 million per year for fiscal years 2026–2030 (to remain available until expended), and includes an explicit rule that no wastewater utility or service provider may be compelled to comply with a surveillance request. For public health agencies, laboratories, utilities, and vendors, the law would create new funding flows and coordination responsibilities while leaving participation voluntary for service providers.
At a Glance
What It Does
The bill requires the Secretary of HHS, acting through the CDC Director, to expand, intensify, and coordinate the National Wastewater Surveillance System to detect and monitor pathogens in wastewater. It authorizes grants, contracts, and cooperative agreements to eligible entities to build or improve wastewater surveillance capacity and provides $150 million per year for FY2026–2030, available until expended.
Who It Affects
Affected parties include CDC and HHS program staff, state and local public health departments, public and private laboratories, wastewater utilities and service providers, academic researchers, and vendors of sampling and molecular testing equipment. Eligible entities for federal awards will be the primary recipients of federal funding for surveillance activities.
Why It Matters
This bill centralizes federal support and technical coordination for wastewater-based epidemiology—an early-warning tool for outbreaks—while creating a predictable multi-year funding window. It also preserves utility autonomy by preventing mandatory participation, which shapes coverage, equity, and the practical footprint of the surveillance network.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.R. 766 adds a new section to the Public Health Service Act that tells HHS and the CDC to scale up the National Wastewater Surveillance System (NWSS). The Department must work with other federal agencies and with state and local public health authorities to expand sampling, lab testing, and data coordination so that wastewater can be used more reliably for public health emergency preparedness and response.
The bill anticipates multiple implementation pathways: awarding grants, issuing contracts, and entering cooperative agreements to establish or improve activities that detect pathogens in wastewater. Because the statute lists example pathogens, the program is oriented toward respiratory and vector-borne viruses currently monitored by public health authorities, but the language is broad enough to include other agents as needed.
The authorization of appropriations is explicit: $150 million annually for five fiscal years, with funds allowed to remain available until spent—an arrangement that supports longer-term infrastructure investments and contracts.Practically, the statute gives CDC formal direction to coordinate data collection standards, laboratory methods, and interagency cooperation, but it stops short of forcing utilities to participate. The bill’s rule of construction clarifies that wastewater utilities and service providers cannot be legally required to comply with surveillance requests; instead, participation will rely on agreements, funding incentives, or voluntary partnerships.
That design shifts the program toward a grant-and-contract model rather than a command-and-control one.Implementation will require CDC to define eligible entities, award criteria, data reporting formats, and technical assistance priorities. Those implementation choices will shape whether the program emphasizes urban centralized systems, targeted sentinel sites, rural coverage, or lab capacity building.
The statutory authorization creates funding capacity but leaves operational details—eligibility, reporting cadence, data governance, and privacy safeguards—to rulemaking and guidance from the agency.
The Five Things You Need to Know
The bill adds Section 2827 to the Public Health Service Act to formally expand the National Wastewater Surveillance System under CDC direction.
It requires HHS (through CDC) to award grants, contracts, or cooperative agreements to eligible entities to establish, maintain, or improve wastewater-based infectious disease surveillance.
The statute authorizes $150,000,000 per fiscal year for FY2026–FY2030, with those funds to remain available until expended.
The text explicitly lists example pathogens for monitoring—SARS–CoV–2, influenza, mpox, dengue, West Nile virus, and respiratory syncytial virus—while not limiting the list to those agents.
A rule of construction states that the law does not require a wastewater utility or service provider to comply with a request for wastewater surveillance, making participation voluntary.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title—SEWER Act
This brief header provision names the statute the 'Surveilling Effluent Water for Epidemic Response Act' (SEWER Act). It has no substantive effect other than providing a citation for the amendment that follows.
Addition of Section 2827—National Wastewater Surveillance System
The bill inserts a new statutory section that directs the Secretary of HHS, via the CDC Director, to expand, intensify, and coordinate NWSS activities to detect and monitor pathogens in wastewater. The provision creates an explicit federal mandate to centralize coordination among federal, state, and local agencies and to prioritize wastewater as a tool for public health emergency preparedness and response.
Authorization of appropriations and funding design
This subsection authorizes $150 million annually for fiscal years 2026 through 2030 and clarifies that the money remains available until expended. That language supports multi-year contracts and infrastructure investments rather than single-year projects, and it signals congressional intent for sustained funding over five years. The statute does not prescribe how funds must be apportioned among grants, contracts, or cooperative agreements, leaving allocation decisions to HHS/CDC.
Voluntary participation by wastewater utilities
Placed outside the new section, the bill includes a rule of construction stating that nothing requires a wastewater utility or service provider to comply with a surveillance request. Legally, this prevents the statute from being read to create compulsory federal authority over utilities and makes federal engagement contingent on voluntary agreements or funding incentives rather than mandates.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State and local public health departments—receive federal funding, technical coordination, and standards to build or scale wastewater surveillance programs and integrate results into outbreak detection and response.
- Public and academic laboratories—become eligible for grants and contracts to expand molecular testing capacity, validate assays, and process wastewater samples, creating sustained workload and revenue streams.
- CDC and federal preparedness programs—gain centralized authority and funding to standardize methods and aggregate wastewater data for national situational awareness.
- Municipalities and utilities that opt in—can access federal funds and technical assistance to upgrade sampling programs, laboratory partnerships, and reporting capabilities without being compelled to participate.
- Vendors of sampling equipment, concentration methods, reagents, and bioinformatics tools—stand to benefit from increased demand as surveillance networks expand and labs scale up testing.
Who Bears the Cost
- Wastewater utilities that participate—incur operational costs (staff time, sample collection, shipping logistics) even when supported by federal awards, and may face administrative burdens to negotiate cooperative agreements.
- State and local agencies—must invest staff time to apply for and administer federal awards, coordinate cross-jurisdictional sampling, and build data pipelines that meet CDC requirements.
- Smaller or regional laboratories—may need capital upgrades to meet federal standards and compete for grants or contracts, creating short-term capacity strain.
- CDC and HHS program offices—will absorb program management, grant oversight, and technical-assistance responsibilities; administrative costs are implicit though appropriation language covers funding generally.
- Data governance and legal teams—must develop agreements, protect sensitive information, and manage community communications, creating compliance workloads for grantees and participating authorities.
Key Issues
The Core Tension
The central tension is between building a nationally coordinated, comparable early-warning system that requires broad, standardized participation and respecting the autonomy of wastewater utilities and local control; the statute funds and coordinates but makes participation voluntary, a trade-off that may improve acceptability while reducing coverage and comparability.
The statute is straightforward in establishing federal support and a coordination role for CDC, but it leaves many consequential choices to agency implementation. The bill does not define 'eligible entities,' set award criteria, require particular reporting standards, or prescribe data-sharing protocols.
Those omissions create room for flexibility but also for uneven implementation: funding could cluster in jurisdictions with grant-writing capacity and existing lab networks while rural or resource-poor areas remain undercovered.
The voluntary participation clause protects utilities from federal compulsion but also risks producing a patchwork surveillance system that undermines representativeness and equity. Because the law authorizes but does not appropriate funds, program scale ultimately depends on future appropriations.
Operational challenges—standardizing sampling frequency, normalizing results across labs, validating methods for different pathogens, and setting thresholds for public-health action—are left to CDC guidance, which will determine the program's public health value and legal exposure for participants.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.